37.79
-1.41 (-3.60%)
| Previous Close | 39.20 |
| Open | 39.69 |
| Volume | 825,014 |
| Avg. Volume (3M) | 1,320,855 |
| Market Cap | 2,259,857,408 |
| Price / Book | 3.78 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2026 |
| Diluted EPS (TTM) | -1.92 |
| Total Debt/Equity (MRQ) | 0.23% |
| Current Ratio (MRQ) | 21.07 |
| Operating Cash Flow (TTM) | -73.96 M |
| Levered Free Cash Flow (TTM) | -45.43 M |
| Return on Assets (TTM) | -21.36% |
| Return on Equity (TTM) | -31.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Enliven Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -4.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.40 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.75% |
| % Held by Institutions | 90.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Orbimed Advisors Llc | 31 Dec 2025 | 7,959,538 |
| Commodore Capital Lp | 31 Dec 2025 | 4,692,809 |
| Vestal Point Capital, Lp | 31 Dec 2025 | 3,830,000 |
| Fairmount Funds Management Llc | 31 Dec 2025 | 3,711,444 |
| Polar Capital Holdings Plc | 31 Dec 2025 | 3,513,680 |
| Vr Adviser, Llc | 31 Dec 2025 | 3,226,331 |
| Janus Henderson Group Plc | 31 Dec 2025 | 1,671,724 |
| Novo Holdings A/S | 31 Dec 2025 | 1,480,000 |
| Capital Research Global Investors | 31 Dec 2025 | 1,304,346 |
| Pictet Asset Management Holding Sa | 31 Dec 2025 | 1,303,235 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COLLINS HELEN LOUISE | - | 35.53 | -40,000 | -1,421,200 |
| Aggregate Net Quantity | -40,000 | |||
| Aggregate Net Value ($) | -1,421,200 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 35.53 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COLLINS HELEN LOUISE | Officer | 25 Mar 2026 | Automatic sell (-) | 40,000 | 35.53 | 1,421,200 |
| COLLINS HELEN LOUISE | Officer | 25 Mar 2026 | Option execute | 40,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones |
| 07 Jan 2026 | Announcement | Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |